Trials

Ongoing trials:

First line of treatment

  • KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
  • HOVON129 - Treatment of primary plasma cell leukemia
  • Hovon147 - Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
  • Ithaca: Isatuximab-Rd vs Rd for patients with high risk smouldering myeloma
  • REMNANT: Two-line study for patients eligible for transplant
  • Magnolia: Zometa 2year vs 4year

Relapse or refractory, patient not eligible for ASCT

  • Melflufen vs Pomalidomide in relapsed myeloma
  • Combined carfilzomib and hydroxychloroquine in patients with relapsed / refractory multiple myeloma – A phase I trial
  • An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
  • A Phase I, open-label, multicenter, study of WVT078 in subjects with relapsed and/or refractory multiple myeloma
  • bb2121 - A phase 3, multicenter, randomized, openlabel study to compare the efficacy and safety of BB2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)

Upcoming trials:

  • AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7297089 IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
 
Page visits: 4943